Colangelo Dominick 4
4 · Trevi Therapeutics, Inc. · Filed Jun 4, 2026
Research Summary
AI-generated summary of this filing
Trevi Therapeutics (TRVI) Director Dominick Colangelo Receives Award
What Happened
Dominick Colangelo, a director of Trevi Therapeutics, was granted a derivative award on June 3, 2026: an option covering 35,000 shares with an acquisition price of $0. The reported acquisition value is $0 because this was an awarded derivative security (not an open‑market purchase or sale). This is a grant of compensation, not an immediate cash investment or sale.
Key Details
- Transaction date: 2026-06-03; Form 4 filed: 2026-06-04 (timely filing).
- Security: derivative award (option) for 35,000 shares; price reported $0.00.
- Vesting: option is scheduled to fully vest on the earlier of (i) the first anniversary of the grant or (ii) the next annual meeting of stockholders, subject to continued service.
- Shares owned after transaction: not specified in the provided filing excerpt.
- No 10b5-1 plan, cashless exercise, tax‑withholding, or sale noted in this filing.
Context
Derivative grants to directors are common as compensation for service; because this award vests over time and is contingent on continued service, it may be forfeited if Colangelo leaves before vesting. Such awards are informational rather than direct market endorsements — they don’t indicate an immediate buy or sell by the insider.
Insider Transaction Report
- Award
Nonstatutory Stock Option (right to buy)
[F1]2026-06-03+35,000→ 35,000 totalExercise: $13.45Exp: 2036-06-02→ Common Stock (35,000 underlying)
Footnotes (1)
- [F1]This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer.